Skip to main content
. 2022 Apr 29;14(9):1879. doi: 10.3390/nu14091879

Figure 2.

Figure 2

The plasma levels of low-density lipoprotein cholesterol (LDL-C) significantly decreased after SAx treatment (oral supplementation with hydroxytyrosol (HT) and punicalagin (PC)) (black color) in subjects with high plasma levels of LDL-C, a risk factor for CVD, (n = 16) (** p < 0.01). This effect was not observed after placebo treatment (gray color). The data represent the adjusted means ± standard deviations (SDs) from multivariate models.